Lynparza Got Prostate Cancer OK, but Reimbursement Issues Remain for CDx Costs: Professor

Japan’s recent prostate cancer nod for the PARP inhibitor Lynparza (olaparib) is good news, but problems remain with the reimbursement of testing costs with FoundationOne CDx Cancer Genome Profile when it is used as a companion diagnostic (CDx), a professor...read more